Novabridge Biosciences (NASDAQ:NBP) & Xenon Pharmaceuticals (NASDAQ:XENE) Head to Head Review

Novabridge Biosciences (NASDAQ:NBP) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Profitability

This table compares Novabridge Biosciences and Xenon Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novabridge Biosciences	N/A	N/A	N/A
Xenon Pharmaceuticals	N/A	-40.68%	-38.79%

Institutional & Insider Ownership

38.4% of Novabridge Biosciences shares are owned by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. 22.1% of Novabridge Biosciences shares are owned by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Novabridge Biosciences has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Novabridge Biosciences and Xenon Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novabridge Biosciences	1	0	1	0	2.00
Xenon Pharmaceuticals	1	1	11	1	2.86

Novabridge Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 938.06%. Xenon Pharmaceuticals has a consensus price target of $71.31, suggesting a potential upside of 72.80%. Given Novabridge Biosciences’ higher probable upside, equities research analysts plainly believe Novabridge Biosciences is more favorable than Xenon Pharmaceuticals.

Valuation and Earnings

This table compares Novabridge Biosciences and Xenon Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novabridge Biosciences	$3.89 million	25.85	-$46.27 million	($0.36)	-2.41
Xenon Pharmaceuticals	N/A	N/A	-$345.91 million	($4.70)	-8.78

Novabridge Biosciences has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Novabridge Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Novabridge Biosciences beats Xenon Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

About Novabridge Biosciences

Novabridge Biosciences (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival. The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.